Gsk (GSK) Long-Term Deferred Tax (2009 - 2026)

Gsk (GSK) has 18 years of Long-Term Deferred Tax data on file, last reported at $8.5 billion in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Deferred Tax fell 3.13% year-over-year to $8.5 billion; the trailing twelve-month figure through Jun 2026 stood at $8.5 billion (down 3.13% YoY), and the FY2025 full-year result was $8.7 billion, changed 0.41% from the prior year.
• Long-Term Deferred Tax was $8.5 billion for Q2 2026 at Gsk, roughly flat from $8.5 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $8.8 billion in Q2 2025 to a low of $421.3 million in Q1 2022.
• A 5-year average of $7.3 billion and a median of $7.6 billion in 2023 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax tumbled 92.91% in 2022 and surged 1518.42% in 2023, its largest moves.
• Gsk's Long-Term Deferred Tax stood at $6.6 billion in 2022, then increased by 13.13% to $7.5 billion in 2023, then grew by 15.52% to $8.7 billion in 2024, then increased by 0.0% to $8.7 billion in 2025, then slipped by 1.93% to $8.5 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $8.5 billion in Q2 2026, $8.5 billion in Q1 2026, and $8.7 billion in Q4 2025.